Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Mucinous Adenocarcinoma of the Colon
Mucinous Adenocarcinoma of the Rectum
Recurrent Colon Cancer
Recurrent Rectal Cancer
Signet Ring Adenocarcinoma of the Colon
Signet Ring Adenocarcinoma of the Rectum
Stage IV Colon Cancer
Stage IV Rectal Cancer
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) and NRAS Wild-Type Metastatic Colorectal Cancer.|
- Progression free survival(PFS) [ Time Frame: Time from study day 1 to the time the patient is first recorded as having disease progression or death, assessed up to 2 years ] [ Designated as safety issue: No ]Continuous variables will be expressed by means, standard deviations and 95% confidence intervals. Estimated using the Kaplan-Meier estimator with confidence interval calculated based on the Brookmeyer-Crowley method.
- Frequency and severity of toxicities of the regimens, graded according to the NCI CTCAE v4.0 [ Time Frame: Up to 2 years ] [ Designated as safety issue: Yes ]Frequencies will be computed for discrete data.
- Overall response rate, as described in RECIST v1.1 criteria [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
- Overall survival [ Time Frame: Time from study day 1 to the date of death or the last date the patient was known to be alive, assessed up to 1 year ] [ Designated as safety issue: No ]Continuous variables will be expressed by means, standard deviations and 95% confidence intervals. Kaplan-Meier estimator will be used.
|Study Start Date:||February 2013|
|Estimated Primary Completion Date:||December 2017 (Final data collection date for primary outcome measure)|
Experimental: Treatment (panitumumab, combination chemotherapy)
5-Fluorouracil, irinotecan, and panitumumab
Other Names:Drug: irinotecan hydrochloride
Other Names:Drug: fluorouracil
Other Names:Drug: leucovorin calcium
I. To determine the median progression-free survival in patients treated with leucovorin calcium, fluorouracil, and irinotecan hydrochloride (FOLFIRI) and panitumumab for K-ras and NRAS wild-type, metastatic colorectal carcinoma who have already progressed on FOLFIRI + Bevacizumab.
I. To determine the frequency and severity of toxicities of the regimens. II. To determine overall response rate. III. To determine the median overall survival and the overall survival rate at 1 year.
Patients receive panitumumab intravenously (IV) over 60-90 minutes, leucovorin calcium IV over 90 minutes, fluorouracil IV continuously over 46 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01814501
|Contact: Ohio State University Comprehensive Cancer Center||1-800-293-5066||Jamesline@osumc.edu|
|Contact: Christina Wu, MD||614-293-6529||Christina.Wu@osumc.edu|
|United States, Ohio|
|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center||Recruiting|
|Columbus, Ohio, United States, 43210|
|Contact: Christina Wu 614-293-9863 Christina.Wu@osumc.edu|
|Principal Investigator: Christina Wu|
|Sub-Investigator: Richard Goldberg, MD|
|Sub-Investigator: Tony Saab, MD|
|Sub-Investigator: Ahmed Ghany, MD|
|United States, Tennessee|
|Vanderbilt-Ingram Cancer Center||Recruiting|
|Nashville, Tennessee, United States, 37232|
|Contact: Emily Chan, MD 615-322-4967 Emily.Chan@vanderbilt.edu|
|Principal Investigator:||Christina Wu||Ohio State University Comprehensive Cancer Center|